AR121806A1 - Uso de vectores virales para la producción de vacunas contra coronavirus - Google Patents

Uso de vectores virales para la producción de vacunas contra coronavirus

Info

Publication number
AR121806A1
AR121806A1 ARP210100942A ARP210100942A AR121806A1 AR 121806 A1 AR121806 A1 AR 121806A1 AR P210100942 A ARP210100942 A AR P210100942A AR P210100942 A ARP210100942 A AR P210100942A AR 121806 A1 AR121806 A1 AR 121806A1
Authority
AR
Argentina
Prior art keywords
production
viral vectors
vaccines against
against coronavirus
coronavirus
Prior art date
Application number
ARP210100942A
Other languages
English (en)
Inventor
Hansell Hall Stedman
Geoffrey Tabin
Charles R Bridges
Original Assignee
4Mvac Llc
Univ Pennsylvania
Charles R Bridges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Mvac Llc, Univ Pennsylvania, Charles R Bridges filed Critical 4Mvac Llc
Publication of AR121806A1 publication Critical patent/AR121806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Composiciones que incluyen AAV y vectores de AAV que incluyen una secuencia que codifica para un polipéptido de SARS-CoV-2 o fragmento del mismo. También se proveen métodos y materiales para elaborar y usar los AAV y vectores de AAV para generar inmunidad contra un coronavirus en un sujeto.
ARP210100942A 2020-04-09 2021-04-09 Uso de vectores virales para la producción de vacunas contra coronavirus AR121806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063007865P 2020-04-09 2020-04-09

Publications (1)

Publication Number Publication Date
AR121806A1 true AR121806A1 (es) 2022-07-13

Family

ID=75625691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100942A AR121806A1 (es) 2020-04-09 2021-04-09 Uso de vectores virales para la producción de vacunas contra coronavirus

Country Status (5)

Country Link
US (1) US20230142780A1 (es)
EP (1) EP4132575A1 (es)
AR (1) AR121806A1 (es)
TW (1) TW202144579A (es)
WO (1) WO2021207592A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11564983B1 (en) 2021-08-20 2023-01-31 Betagen Scientific Limited Efficient expression system of SARS-CoV-2 receptor binding domain (RBD), methods for purification and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US7557197B2 (en) 2004-01-28 2009-07-07 Oregon Health & Science University Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
GB201708444D0 (en) * 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response

Also Published As

Publication number Publication date
WO2021207592A1 (en) 2021-10-14
EP4132575A1 (en) 2023-02-15
US20230142780A1 (en) 2023-05-11
TW202144579A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
CO2019014677A2 (es) Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos
PE20180241A1 (es) Adenovirus oncolitico que codifica una proteina b7
CL2020003176A1 (es) Novedosas proteínas de la cápside del virus adenoasociado (divisional sol. 201900167).
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
CL2022000774A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
AR121806A1 (es) Uso de vectores virales para la producción de vacunas contra coronavirus
CL2023001793A1 (es) Anticuerpos anti-componente de complemento y métodos de uso
CO2023009285A2 (es) Vacunas contra el vih y métodos de uso
CL2021001713A1 (es) Resinas fenólicas del tipo novolaca, proceso de síntesis de dichas resinas fenólicas y uso de las mismas
CL2019000655A1 (es) Nuevo sitio de inserción orf70 de ehv.
UY36995A (es) Proteínas de fusión de e2 y fmdv y sus usos
CO2021009271A2 (es) Rhabdovirus recombinante que codifica ccl21
CO2023000493A2 (es) Vectores de hvt recombinantes que expresan hemaglutinina de influenza y composiciones inmunogénicas, y producción y usos de estos
AR115002A1 (es) Ehv con ul18 y/o ul8 inactivados
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
CL2022003404A1 (es) Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80
AR119105A1 (es) Célula mutante bloqueada mdbk irf3 / irf7 y su uso para producción de vacunas
PE20171769A1 (es) Obtencion de una salmonella enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar
UY36860A (es) Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos
CL2022001176A1 (es) Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducida
PE20211141A1 (es) Salmonella enteritidis recombinante y su uso como vacuna porcina